Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Moodys
McKesson
Baxter
Merck

Last Updated: June 29, 2022

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Empagliflozin; Linagliptin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01422876 ↗ Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed Eli Lilly and Company Phase 3 2011-08-01 This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
NCT01422876 ↗ Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients Completed Boehringer Ingelheim Phase 3 2011-08-01 This trial will evaluate use of BI 10773/linagliptin once daily (qd) fixed dose combination (FDC) in treatment naïve and metformin treated patients with type 2 diabetes mellitus to support approval by regulatory authorities.
NCT01734785 ↗ Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2013-01-01 This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
NCT01734785 ↗ Safety and Efficacy of the Combination of Empagliflozin and Linagliptin Compared to Linagliptin Alone Over 24 Weeks in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2013-01-01 This trial compare the use of two different doses of Empagliflozin to placebo, in T2DM patients on 16 wks linagliptin treatment and metformin background therapy.
NCT01778049 ↗ Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2013-01-01 The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.
NCT01778049 ↗ Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2013-01-01 The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum tolerated dose of metformin. The primary objective of efficacy evaluation is planned after 24 weeks of treatment. The study is designed to show superiority of the combination of empagliflozin and linagliptin over empagliflozin alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin; Linagliptin; Metformin Hydrochloride

Condition Name

Condition Name for Empagliflozin; Linagliptin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 4
Healthy 3
Type 2 Diabetes Mellitus 2
Impaired Glucose Tolerance 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Empagliflozin; Linagliptin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 8
Diabetes Mellitus 7
Insulin Resistance 2
Glucose Intolerance 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Empagliflozin; Linagliptin; Metformin Hydrochloride

Trials by Country

Trials by Country for Empagliflozin; Linagliptin; Metformin Hydrochloride
Location Trials
United States 83
Canada 14
Australia 9
Germany 7
Mexico 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Empagliflozin; Linagliptin; Metformin Hydrochloride
Location Trials
Georgia 4
Florida 4
California 4
Texas 4
North Carolina 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Empagliflozin; Linagliptin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin; Linagliptin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Empagliflozin; Linagliptin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 8
Recruiting 5
Unknown status 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Empagliflozin; Linagliptin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Empagliflozin; Linagliptin; Metformin Hydrochloride
Sponsor Trials
Boehringer Ingelheim 7
Eli Lilly and Company 6
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Empagliflozin; Linagliptin; Metformin Hydrochloride
Sponsor Trials
Other 17
Industry 14
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
Colorcon
AstraZeneca
McKinsey
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.